

El Salvador

Tuberculosis profile

Population 2016

6.3 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.077 (0.047–0.11)	1.2 (0.74–1.8)
Mortality (HIV+TB only)	0.053 (0.037–0.072)	0.84 (0.59–1.1)
Incidence (includes HIV+TB)	3.8 (2.9–4.8)	60 (46–76)
Incidence (HIV+TB only)	0.26 (0.17–0.37)	4.1 (2.6–5.8)
Incidence (MDR/RR-TB)**	0.14 (0.076–0.21)	2.2 (1.2–3.3)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	0.21 (0.16–0.26)	1 (0.76–1.3)	1.2 (0.92–1.5)
Males	0.24 (0.18–0.3)	2.3 (1.7–2.9)	2.6 (1.9–3.2)
Total	0.45 (0.33–0.56)	3.3 (2.5–4.2)	3.8 (2.9–4.8)

TB case notifications, 2016

Total cases notified	3 050
Total new and relapse	3 034
- % tested with rapid diagnostics at time of diagnosis	12%
- % with known HIV status	98%
- % pulmonary	87%
- % bacteriologically confirmed among pulmonary	90%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	80% (63–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.04 (0.02–0.05)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	201	7%
- on antiretroviral therapy	193	96%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			79 (40–120)
Estimated % of TB cases with MDR/RR-TB	2.9% (1.4–4.5)	4.1% (1.3–9.2)	
% notified tested for rifampicin resistance	49%	35%	1 460
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 7, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 6, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	92%	2 452
Previously treated cases, excluding relapse, registered in 2015	56%	9
HIV-positive TB cases registered in 2015	74%	182
MDR/RR-TB cases started on second-line treatment in 2014	73%	15
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	10% (9.4–11)

TB financing, 2017

National TB budget (US\$ millions)	5.9
Funding source: 24% domestic, 76% international, 0% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

